Rodman & Renshaw Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $50

Benzinga · 10/11 14:04
Rodman & Renshaw analyst Elemer Piros initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $50.